CKD-mineral & bone disorder
ckd-mbd · society: KDIGO
Summary
Selective update of the 2009 KDIGO CKD-MBD guideline addressing diagnosis and treatment of mineral and bone disorders in CKD G3a–G5D and kidney transplant recipients. Key revisions: BMD testing is now recommended (rather than discouraged) because newer cohort data show DXA predicts fracture in CKD; phosphate-lowering therapy is reserved for overt/progressive hyperphosphatemia rather than preventive normalization; calcium-based phosphate binders should be restricted across all CKD stages (not only with hypercalcemia); routine calcitriol/vitamin D analogs are not recommended in CKD G3a–G5 non-dialysis due to hypercalcemia risk; and calcimimetics, calcitriol, or vitamin D analogs are all acceptable first-line PTH-lowering options in CKD G5D.
Current guideline: KDIGO 2017 CKD-MBD Update · 
download Anki sub-deck
Versions
- 2017 · KDIGO — KDIGO 2017 CKD-MBD Update